Q3 Earnings Estimate for Surmodics Issued By Zacks Research

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Zacks Research issued their Q3 2025 earnings per share estimates for Surmodics in a research note issued on Wednesday, May 21st. Zacks Research analyst D. Dey expects that the company will earn ($0.18) per share for the quarter. The consensus estimate for Surmodics' current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics' Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.44) EPS, Q1 2026 earnings at ($0.11) EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.06 EPS, FY2026 earnings at ($0.01) EPS, Q1 2027 earnings at $0.02 EPS and Q2 2027 earnings at $0.12 EPS.

Surmodics (NASDAQ:SRDX - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.07). The business had revenue of $28.09 million for the quarter, compared to analyst estimates of $32.23 million. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%.

Several other equities research analysts also recently weighed in on the stock. Lake Street Capital upgraded shares of Surmodics from a "hold" rating to a "buy" rating and set a $43.00 target price for the company in a research note on Friday, March 7th. Needham & Company LLC reiterated a "hold" rating on shares of Surmodics in a research report on Wednesday, April 30th. Finally, Wall Street Zen assumed coverage on Surmodics in a research note on Monday, February 3rd. They issued a "hold" rating on the stock.

Surmodics Stock Performance

Shares of Surmodics stock traded down $0.43 on Monday, hitting $29.11. The stock had a trading volume of 1,391 shares, compared to its average volume of 193,129. The stock has a market cap of $416.17 million, a price-to-earnings ratio of -28.82 and a beta of 1.32. Surmodics has a 52-week low of $26.00 and a 52-week high of $42.44. The company's 50 day moving average price is $28.75 and its 200 day moving average price is $33.63. The company has a current ratio of 5.45, a quick ratio of 4.29 and a debt-to-equity ratio of 0.26.

Institutional Trading of Surmodics

Several large investors have recently added to or reduced their stakes in the business. R Squared Ltd bought a new position in Surmodics during the fourth quarter valued at approximately $55,000. Strs Ohio bought a new stake in shares of Surmodics during the first quarter valued at approximately $122,000. Legal & General Group Plc grew its position in shares of Surmodics by 34.2% during the 4th quarter. Legal & General Group Plc now owns 3,452 shares of the company's stock worth $137,000 after buying an additional 880 shares during the period. Price T Rowe Associates Inc. MD bought a new stake in Surmodics in the fourth quarter valued at approximately $217,000. Finally, AlphaQuest LLC acquired a new stake in Surmodics during the 1st quarter worth approximately $232,000. 96.63% of the stock is currently owned by institutional investors and hedge funds.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).